title: [Prognostic evaluation of comorbidities in patients with myelodysplastic syndrome].
abstract: OBJECTIVE
  To discuss the impact of comorbidities on the outcomes of patients with MDS.
  
  
  METHODS
  The clinical characteristics of 676 MDS patients with detailed comorbidities evaluations was analyzed retrospectively.
  
  
  RESULTS
  There were 395/676 cases (58.4%) with comorbidities (group 1), 281/676 cases (41.6%) without (group 2). Significant differences were seen in the distribution of age (≥ 60 y), bone marrow blasts, abnormal karyotype, WHO 2008 subtypes and IPSS-R risk cohorts (P<0.05) between the two groups. While gender, HGB concentrations, WBC levels, platelet levels and serum ferritin were not significantly different (P>0.05). Independent prognostic significance of comorbidities was seen in both uni-variate and multi-variate analyses (P<0.001). According to MDS-specific comorbidity index (MDS-CI), the median survival were 32(1-153) months, 19(2-85) months and 13(1-37) months in the low-risk, intermediate-risk and high-risk cohorts respectively, while 96(1-166) months in cohorts without any comorbidities, of which significant differences were seen (P<0.001). The MDS-CI allowed further stratification in the IPSS-R low-risk, intermediate-risk and high-risk cohorts (P<0.001).
  
  
  CONCLUSIONS
  Comorbidities provides prognostic stratification independently of IPSS-R for MDS patients.
authors: Institute of Hematology and Hospital of Blood Disease, Chinese Academe of Medical Scienses & Peking Union Medical College, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors: Yi
authors: Y
authors: Li
authors: Institute of Hematology and Hospital of Blood Disease, Chinese Academe of Medical Scienses & Peking Union Medical College, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors: Tiejun
authors: T
authors: Qin
authors: Institute of Hematology and Hospital of Blood Disease, Chinese Academe of Medical Scienses & Peking Union Medical College, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors: Zefeng
authors: Z
authors: Xu
authors: Institute of Hematology and Hospital of Blood Disease, Chinese Academe of Medical Scienses & Peking Union Medical College, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors: Yue
authors: Y
authors: Zhang
authors: Institute of Hematology and Hospital of Blood Disease, Chinese Academe of Medical Scienses & Peking Union Medical College, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors: Liwei
authors: L
authors: Fang
authors: Institute of Hematology and Hospital of Blood Disease, Chinese Academe of Medical Scienses & Peking Union Medical College, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors: Hongli
authors: H
authors: Zhang
authors: Institute of Hematology and Hospital of Blood Disease, Chinese Academe of Medical Scienses & Peking Union Medical College, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors: Lijuan
authors: L
authors: Pan
authors: Institute of Hematology and Hospital of Blood Disease, Chinese Academe of Medical Scienses & Peking Union Medical College, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors: Naibo
authors: N
authors: Hu
authors: Institute of Hematology and Hospital of Blood Disease, Chinese Academe of Medical Scienses & Peking Union Medical College, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors: Shiqiang
authors: S
authors: Qu
authors: Institute of Hematology and Hospital of Blood Disease, Chinese Academe of Medical Scienses & Peking Union Medical College, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors: Bing
authors: B
authors: Li
authors: Institute of Hematology and Hospital of Blood Disease, Chinese Academe of Medical Scienses & Peking Union Medical College, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors: Zhijian
authors: Z
authors: Xiao
mesh_terms: D059786:Abnormal Karyotype; D001792:Blood Platelets; D015897:Comorbidity; D006801:Humans; D007962:Leukocytes; D009190:Myelodysplastic Syndromes; D011379:Prognosis; D012189:Retrospective Studies; D012306:Risk